findmyKOL

Robert Toto, MD

Enriched profile

Mary M. Conroy Professor of Kidney Disease, Department of Internal Medicine; Distinguished Teaching Professor; Associate Dean of Clinical and Translational Research, Graduate School of Biomedical Sciences · The University of Texas Southwestern Medical Center

ORCIDNPI
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyNephrologyFocusChronic Kidney Disease and Diabetes+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1986–2026

Robert Toto is Mary M. Conroy Professor of Kidney Disease, Department of Internal Medicine; Distinguished Teaching Professor; Associate Dean of Clinical and Translational Research, Graduate School of Biomedical Sciences at The University of Texas Southwestern Medical Center. OpenAlex indexes 390 publications with 33,663 citations (h-index 81); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Nephrology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Robert Toto, MD, is Mary M. Conroy Professor of Kidney Disease, Department of Internal Medicine at The University of Texas Southwestern Medical Center. The public record shows 390 publications with 33,663 citations (h-index 81), centered on Chronic Kidney Disease and Diabetes, Diabetes Treatment and Management, Blood Pressure and Hypertension Studies. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 14 companies, 22 NIH-funded awards (1986–2026).

  • Most recent indexed publication: 2026 · Kidney360
  • Top research focus: Chronic Kidney Disease and Diabetes
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Chronic Kidney Disease2 trialsHypertension2 trialsAcute Kidney Injury2 trialsRenal Insufficiency2 trialsType 2 Diabetes1 trialType 1 Diabetes1 trialRenal Insufficiency, Chronic1 trialESRD / Dialysis

Research focus

OpenAlex concept fingerprint
Chronic Kidney Disease and DiabetesDiabetes Treatment and ManagementBlood Pressure and Hypertension StudiesDialysis and Renal Disease ManagementRenal Diseases and Glomerulopathies

Drugs & molecules

across trials, industry payments and publications
Farxigageneric · DapagliflozinClinical trialsIndustry payments1Publications10Aranespgeneric · Darbepoetin alfaClinical trialsIndustry payments6Publications2Tradjentageneric · LinagliptinClinical trialsIndustry payments2Publications1

Works with

trial sponsors and companies reporting payments
AstraZeneca UK LimitedClinical trialsIndustry payments12Amgen Inc.Clinical trialsIndustry payments8AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments6

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
390publications

Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.

33,663citations

Total citations across indexed works.

81h-index

Hirsch index (OpenAlex). i10-index 222.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
22NIH grants · 1986–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    70.4%
    Angiotensin receptor blocker (ARB)31.8%
    Losartan Potassium60%Telmisartan40%
    Part D<11 patients
    Loop diuretic12.8%
    Torsemide100%
    Part D12 patients
  • Metabolism & gastrointestinal

    29.6%
    SGLT2 inhibitor15.6%
    Farxiga100%
    Part D<11 patients
    Vitamin D3 Analog7.8%
    Calcitriol100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

22 NIH research awards on record, funded 19862026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

6 congress contributions (2019–2022) across ADA, ENDO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-toto-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    pmc.ncbi.nlm.nih.gov/articles/PMC9076781

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
7 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
5 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.